XML 37 R30.htm IDEA: XBRL DOCUMENT
v3.25.3

Collaboration and License Agreements (Details) - USD ($) $ in Thousands |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Nov. 07, 2022 | Sep. 14, 2018 | Sep. 14, 2018 | May 31, 2024 | Jun. 30, 2022 | Sep. 30, 2025 | Sep. 30, 2024 | Mar. 31, 2024 | Sep. 30, 2025 | Sep. 30, 2024 | Jun. 30, 2025 | Dec. 31, 2024 | Aug. 31, 2024 | Nov. 30, 2023 | Dec. 31, 2021 | Dec. 31, 2020
Collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  | $ 1,741 | $ 3,074 |  | $ 5,277 | $ 11,771 |  |  |  |  |  |
Proceeds from issuance of private placement |  |  |  |  |  |  |  | $ 19,996 |  |  |  |  |  |  |  |
Income expense in change in fair value of the stock price appreciation milestones |  |  |  |  |  | 2,485 | 4,699 |  | 9,042 | 14,419 |  |  |  |  |  |
Candidate 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical development milestone fees |  |  |  | $ 5,000 |  |  |  |  |  |  |  |  |  |  |  |
Ono Pharmaceutical Company Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payments recorded as deferred revenue |  |  | $ 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payments recorded as deferred revenue |  | $ 10,000 | 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate research and development fees payments receivable |  | 20,000 | 20,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement potential additional milestones |  | 44,500 | $ 44,500 |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price of the agreement |  | 54,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  | 1,700 | 3,100 |  | 5,300 | 11,800 |  |  |  |  |  |
Ono Pharmaceutical Company Ltd | Candidate 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of reduction on milestone payments |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Ono Pharmaceutical Company Ltd | Candidate 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  | 10,000 | $ 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment under Deferred revenue |  | 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement annual payments receivable recorded as deferred revenue |  | $ 5,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contra research and development expenses |  |  |  |  |  | 1,300 | 1,700 |  | 4,500 | 3,600 |  |  |  |  |  |
Option exercise payment | $ 12,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ono Pharmaceutical Company Ltd | Minimum | Candidate 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Profits and losses sharing percentage |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement potential additional milestones |  |  |  |  | $ 9,300 |  |  |  |  |  |  |  |  | $ 1,400 |  |
Ono Pharmaceutical Company Ltd | Minimum | Candidate 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement potential additional milestones |  |  |  |  |  |  |  |  |  |  | $ 6,500 |  | $ 7,300 |  |  |
Ono Pharmaceutical Company Ltd | Maximum | Candidate 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement potential additional milestones |  |  |  |  | $ 29,300 |  |  |  |  |  |  |  |  | $ 30,700 |  |
Ono Pharmaceutical Company Ltd | Maximum | Candidate 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate milestone payments |  |  | $ 843,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Ono Pharmaceutical Company Ltd | Maximum | Candidate 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement potential additional milestones |  |  |  |  |  |  |  |  |  |  | $ 44,500 |  | $ 38,000 |  |  |
Amended Mskcc License |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Enterprise value milestone payment |  |  |  |  |  | 75,000 |  |  | 75,000 |  |  |  |  |  |  |
Stock price appreciation milestone payable |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 20,000 |
Enterprise value milestones liability at fair value |  |  |  |  |  | 400 |  |  | 400 |  |  | $ 500 |  |  |  |
Amended MSK License |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Income expense in change in fair value of the stock price appreciation milestones |  |  |  |  |  | $ 100 | $ 100 |  | $ 100 | $ 100 |  |  |  |  |  |
Ono Letter Agreement | Ono Pharmaceutical Company Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000

X
- Definition Clinical Development Milestone Fees + References No definition available. + Details
Name: | fate_ClinicalDevelopmentMilestoneFees
Namespace Prefix: | fate_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative arrangement aggregate milestone payments receivable. + References No definition available. + Details
Name: | fate_CollaborativeArrangementAggregateMilestonePaymentsReceivable
Namespace Prefix: | fate_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative arrangement aggregate payments receivable. + References No definition available. + Details
Name: | fate_CollaborativeArrangementAggregatePaymentsReceivable
Namespace Prefix: | fate_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaborative arrangement annual payments receivable recorded under deferred revenue. + References No definition available. + Details
Name: | fate_CollaborativeArrangementAnnualPaymentsReceivableRecordedUnderDeferredRevenue
Namespace Prefix: | fate_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative arrangement percentage of reduction on milestone payments. + References No definition available. + Details
Name: | fate_CollaborativeArrangementPercentageOfReductionOnMilestonePayments
Namespace Prefix: | fate_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative arrangement potential additional milestones. + References No definition available. + Details
Name: | fate_CollaborativeArrangementPotentialAdditionalMilestones
Namespace Prefix: | fate_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents the amount of upfront payments received under collaborative arrangements is recorded as deferred revenue. + References No definition available. + Details
Name: | fate_CollaborativeArrangementsUpfrontPaymentsRecordedUnderDeferredRevenue
Namespace Prefix: | fate_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contra research and development expenses + References No definition available. + Details
Name: | fate_ContraResearchAndDevelopmentExpenses
Namespace Prefix: | fate_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Enterprise value milestone payment. + References No definition available. + Details
Name: | fate_EnterpriseValueMilestonePayment
Namespace Prefix: | fate_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Enterprise Value Milestones Liability At Fair Value. + References No definition available. + Details
Name: | fate_EnterpriseValueMilestonesLiabilityAtFairValue
Namespace Prefix: | fate_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone Payment Under Deferred Revenue + References No definition available. + Details
Name: | fate_MilestonePaymentUnderDeferredRevenue
Namespace Prefix: | fate_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payments during the period. + References No definition available. + Details
Name: | fate_MilestonePayments
Namespace Prefix: | fate_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Option exercise payment. + References No definition available. + Details
Name: | fate_OptionExercisePayment
Namespace Prefix: | fate_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Profit loss sharing percentage. + References No definition available. + Details
Name: | fate_ProfitLossSharingPercentage
Namespace Prefix: | fate_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Stock price appreciation milestone payable. + References No definition available. + Details
Name: | fate_StockPriceAppreciationMilestonePayable
Namespace Prefix: | fate_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Transaction price of agreement. + References No definition available. + Details
Name: | fate_TransactionPriceOfAgreement
Namespace Prefix: | fate_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront non-refundable non-creditable payment receivable. + References No definition available. + Details
Name: | fate_UpfrontNonRefundableNonCreditablePaymentReceivable
Namespace Prefix: | fate_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of income (expense) related to nonoperating activities, classified as other. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_OtherNonoperatingIncomeExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfPrivatePlacement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_TitleOfIndividualAxis=fate_CandidateTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=fate_OnoPharmaceuticalCompanyLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=fate_CandidateOneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_TitleOfIndividualAxis=fate_CandidateThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=fate_AmendedMskccLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=fate_AmendedMSKLicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=fate_OnoLetterAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |